METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY
The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determing the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | PAUL DELMAR DIETHER LAMBRECHTS STEFAN SCHERER SANNE LYSBET DE HAAS |
| description | The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determing the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.
La invención se refiere a un método de predicción de la susceptibilidad de un paciente a desarrollar hipertensión asociada a un tratamiento antiangiogénesis, tal como bevacizumab, mediante la determinación del genotipo del gen KDR y/o del gen EGF. La invención se refiere además a una composición farmacéutica que comprende un inhibidor de la angiogénesis, tal como bevacizumab, para el tratamiento de un paciente que sufre de un cáncer, basado en el genotipo del gen KDR y/o EGF. La invención se refiere además a un método para reducir el riesgo de hipertensión asociado a una terapia antiangiogénesis, tal como bevacizumab, en un paciente que sufre de cáncer, mediante la determinación del genotipo del gen KDR y/o del gen EGF. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MX2014002307A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MX2014002307A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MX2014002307A3</originalsourceid><addsrcrecordid>eNqNyrEKwjAQANAsDqL-w-FeiK3gHJJLckiTkBzUTqVInEQL9f9x8QOc3vK2gntkHw3YmCFlNKSZgoNM5QrRgh8TZsZQKAZQpURNitHAQOxBBaZGBUfRYcBCBdhjVmnci81jfq718HMnjhZZ-6Yu76muy3yvr_qZ-lsrT2cp205eVPdX-gKxhjDg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY</title><source>esp@cenet</source><creator>PAUL DELMAR ; DIETHER LAMBRECHTS ; STEFAN SCHERER ; SANNE LYSBET DE HAAS</creator><creatorcontrib>PAUL DELMAR ; DIETHER LAMBRECHTS ; STEFAN SCHERER ; SANNE LYSBET DE HAAS</creatorcontrib><description>The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determing the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.
La invención se refiere a un método de predicción de la susceptibilidad de un paciente a desarrollar hipertensión asociada a un tratamiento antiangiogénesis, tal como bevacizumab, mediante la determinación del genotipo del gen KDR y/o del gen EGF. La invención se refiere además a una composición farmacéutica que comprende un inhibidor de la angiogénesis, tal como bevacizumab, para el tratamiento de un paciente que sufre de un cáncer, basado en el genotipo del gen KDR y/o EGF. La invención se refiere además a un método para reducir el riesgo de hipertensión asociado a una terapia antiangiogénesis, tal como bevacizumab, en un paciente que sufre de cáncer, mediante la determinación del genotipo del gen KDR y/o del gen EGF.</description><language>eng ; spa</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2014</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140826&DB=EPODOC&CC=MX&NR=2014002307A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20140826&DB=EPODOC&CC=MX&NR=2014002307A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PAUL DELMAR</creatorcontrib><creatorcontrib>DIETHER LAMBRECHTS</creatorcontrib><creatorcontrib>STEFAN SCHERER</creatorcontrib><creatorcontrib>SANNE LYSBET DE HAAS</creatorcontrib><title>METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY</title><description>The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determing the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.
La invención se refiere a un método de predicción de la susceptibilidad de un paciente a desarrollar hipertensión asociada a un tratamiento antiangiogénesis, tal como bevacizumab, mediante la determinación del genotipo del gen KDR y/o del gen EGF. La invención se refiere además a una composición farmacéutica que comprende un inhibidor de la angiogénesis, tal como bevacizumab, para el tratamiento de un paciente que sufre de un cáncer, basado en el genotipo del gen KDR y/o EGF. La invención se refiere además a un método para reducir el riesgo de hipertensión asociado a una terapia antiangiogénesis, tal como bevacizumab, en un paciente que sufre de cáncer, mediante la determinación del genotipo del gen KDR y/o del gen EGF.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2014</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrEKwjAQANAsDqL-w-FeiK3gHJJLckiTkBzUTqVInEQL9f9x8QOc3vK2gntkHw3YmCFlNKSZgoNM5QrRgh8TZsZQKAZQpURNitHAQOxBBaZGBUfRYcBCBdhjVmnci81jfq718HMnjhZZ-6Yu76muy3yvr_qZ-lsrT2cp205eVPdX-gKxhjDg</recordid><startdate>20140826</startdate><enddate>20140826</enddate><creator>PAUL DELMAR</creator><creator>DIETHER LAMBRECHTS</creator><creator>STEFAN SCHERER</creator><creator>SANNE LYSBET DE HAAS</creator><scope>EVB</scope></search><sort><creationdate>20140826</creationdate><title>METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY</title><author>PAUL DELMAR ; DIETHER LAMBRECHTS ; STEFAN SCHERER ; SANNE LYSBET DE HAAS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MX2014002307A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; spa</language><creationdate>2014</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>PAUL DELMAR</creatorcontrib><creatorcontrib>DIETHER LAMBRECHTS</creatorcontrib><creatorcontrib>STEFAN SCHERER</creatorcontrib><creatorcontrib>SANNE LYSBET DE HAAS</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PAUL DELMAR</au><au>DIETHER LAMBRECHTS</au><au>STEFAN SCHERER</au><au>SANNE LYSBET DE HAAS</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY</title><date>2014-08-26</date><risdate>2014</risdate><abstract>The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determing the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.
La invención se refiere a un método de predicción de la susceptibilidad de un paciente a desarrollar hipertensión asociada a un tratamiento antiangiogénesis, tal como bevacizumab, mediante la determinación del genotipo del gen KDR y/o del gen EGF. La invención se refiere además a una composición farmacéutica que comprende un inhibidor de la angiogénesis, tal como bevacizumab, para el tratamiento de un paciente que sufre de un cáncer, basado en el genotipo del gen KDR y/o EGF. La invención se refiere además a un método para reducir el riesgo de hipertensión asociado a una terapia antiangiogénesis, tal como bevacizumab, en un paciente que sufre de cáncer, mediante la determinación del genotipo del gen KDR y/o del gen EGF.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; spa |
| recordid | cdi_epo_espacenet_MX2014002307A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE |
| title | METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T01%3A49%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PAUL%20DELMAR&rft.date=2014-08-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMX2014002307A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |